Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
PSTI develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.
PSTI also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS.
PSTI has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication.
Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
March 16, 2021
RegMed Investors’ (RMi) pre-open: whack-a-mole
35 companies, 1 interpreter!
Insight, foresight and recommendation
Pluristem (PSTI) – Opened 2018 at $1.44, saw a high of $1.61 and started 2/1 at $1.47 with 2/21 having slipped to $1.38. News is always an appreciator that is never followed through ... PSTI needs to refine its communication to shareholders and operates on assumptions. With $36M of cash on hand and pivotal studies (three) being paid for by grants, estimates assume a quarterly cash burn rate of $8M – I am still a critic expecting data readouts from three of its clinical programs in 2018. Traders "play" the shares - too often ...hold
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors